Genomind, the King of Prussia mental health care company, is expanding its genetic partnership with Albertsons, owner and operator of Acme Markets, writes John George for the Philadelphia Business Journal.
The expanded deal will provide Albertsons with the option of offering patients Genomind’s genetic testing services. This will allow them to make more informed decisions about their mental health medication management.
Genomind’s flagship product is the Professional PGx Express. This uses a cheek swab to generate genetic profiles that indicate what medications are likely to be the most effective in that patient for various mental health conditions.
Specially trained pharmacists at Acme pharmacies statewide and select Albertsons pharmacies in Idaho will offer the test to patients. They will also have access to Genomind’s software system G-DIG, which provides updated information on the ways certain drugs may interact with patient genotypes and with other drugs.
Additionally, the 28 pharmacies from the original deal have now increased to 59 locations nationwide.
According to Janis Levit, director of pharmacy operations for Acme Markets, the goal of the expanded partnership is to “help more patients, and their providers, better manage their medications and live happier, healthier lives.”
Read more about Genomind at the Philadelphia Business Journal by clicking here.